Fairvalue-Calculator Fairvalue-Calculator

Shanghai Allist Pharmaceuticals Co (688578) Fair Value & Analysis

Healthcare · CN · Market cap 37.4B CNY

Price¥85.50
Fair Value¥82.57
Upside-3.4%
Quality80/100
Evidence: Medium Range ¥62.25 – ¥292.77

Analysis

Shanghai Allist Pharmaceuticals Co (688578) currently trades at ¥85.50, while our model-based Fair Value estimate is ¥82.57 — implying the stock looks roughly 3.4% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.